Mineralys Therapeutics Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Jon Congleton
Chief executive officer
US$5.4m
Total compensation
| CEO salary percentage | 9.7% |
| CEO tenure | 4yrs |
| CEO ownership | 1.8% |
| Management average tenure | 1.8yrs |
| Board average tenure | 2.5yrs |
Recent management updates
Recent updates
Here's Why We're Not Too Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation
Oct 07
Mineralys In Hypertension: Upcoming Catalysts And Strong Positioning
Sep 17We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Jun 06Mineralys Therapeutics: A Story To Keep An Eye On
Mar 18Mineralys: 2nd Half 2024 Hypertension Data Readout
Feb 09We're Hopeful That Mineralys Therapeutics (NASDAQ:MLYS) Will Use Its Cash Wisely
Nov 12We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Jul 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$153m |
| Jun 30 2024 | n/a | n/a | -US$120m |
| Mar 31 2024 | n/a | n/a | -US$91m |
| Dec 31 2023 | US$5m | US$517k | -US$72m |
| Sep 30 2023 | n/a | n/a | -US$57m |
| Jun 30 2023 | n/a | n/a | -US$40m |
| Mar 31 2023 | n/a | n/a | -US$35m |
| Dec 31 2022 | US$2m | US$417k | -US$30m |
| Sep 30 2022 | n/a | n/a | -US$28m |
| Dec 31 2021 | US$675k | US$346k | -US$19m |
Compensation vs Market: Jon's total compensation ($USD5.36M) is above average for companies of similar size in the US market ($USD2.24M).
Compensation vs Earnings: Jon's compensation has increased whilst the company is unprofitable.
CEO
Jon Congleton (61 yo)
4yrs
Tenure
US$5,355,257
Compensation
Mr. Jon Congleton serves as Chief Executive Officer and Director at Mineralys Therapeutics, Inc. since November 2020. He serves as an Operating Partner at Catalys Pacific. He was the Chief Executive Office...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 5.5yrs | US$630.13k | no data | |
| CEO & Director | 4yrs | US$5.36m | 1.8% $ 10.6m | |
| CFO & Secretary | 2.7yrs | US$2.19m | 0.48% $ 2.8m | |
| Chief Medical Officer | 3.8yrs | US$2.35m | 0.28% $ 1.7m | |
| Executive Vice President of Operations | 1.8yrs | no data | no data | |
| Vice President of Human Resources | less than a year | no data | no data | |
| Senior Vice President of CMC | no data | no data | no data | |
| Senior Vice President of Quality Assurance | no data | no data | no data | |
| Senior Vice President of Regulatory Affairs | no data | no data | no data | |
| Senior Vice President of Clinical Operations | 1.8yrs | no data | no data | |
| Chief Business Officer | less than a year | no data | no data | |
| Senior Vice President of Clinical Development | less than a year | no data | no data |
1.8yrs
Average Tenure
54yo
Average Age
Experienced Management: MLYS's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 5.5yrs | US$630.13k | no data | |
| CEO & Director | 4yrs | US$5.36m | 1.8% $ 10.6m | |
| Independent Director | 1.2yrs | US$427.02k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$607.30k | 0% $ 0 | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 1.2yrs | US$428.52k | 0% $ 0 | |
| Director | less than a year | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 2.5yrs | US$611.91k | 0% $ 0 | |
| Member of Clinical Advisory Board | no data | no data | no data |
2.5yrs
Average Tenure
56yo
Average Age
Experienced Board: MLYS's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.